ProCE Banner Activity

DREAMM-7 Efficacy Update: Belantamab Mafodotin Plus Bortezomib, Dexamethasone vs Daratumumab Plus Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Conference Coverage
Slideset

Updated efficacy results from DREAMM-7 showed significant improvement in OS with BVd vs DVd in patients with R/R MM.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation